Bayern Kapital

What they fund

• Geographic Focus — Exclusively targets innovative startups and scale-ups located in Bavaria, Germany, positioning itself as the primary partner for regional technology growth [1][3].
• Sector Focus — Concentrates on High-Tech, DeepTech, and Life Sciences sectors, investing across all technology areas within these domains [1].
• Investment Stage — Covers the entire lifecycle from Pre-Seed through growth phases to Scale-up, acting as a consistent partner from early ideation to maturity [1].
• Ticket Size — Deploys capital ranging from €250,000 to €50 million per company, allowing for significant participation in later-stage rounds [1].
• Role — Functions as an anchor investor on equal footing, providing long-term support and capital across multiple financing rounds rather than one-off transactions [1].

Investment thesis

Bayern Kapital exists to finance and accompany technology-oriented start-ups and scale-ups in Bavaria, acting as a long-term anchor investor from pre-seed through growth phases. It aims to sustain regional innovation and economic value creation in the Free State of Bavaria.

• Strategic anchor investor: Invests €250,000 to €50 million per company, often co-investing with private VCs, business angels, and family offices in a 50:50 ratio to leverage private capital. [1]
• Sector focus: Targets high-tech, deep tech, and life sciences, specifically B2B technology companies that build or maintain significant value creation in Bavaria. [2][1]
• Lifecycle coverage: Supports companies from early pre-seed rounds (often alongside angels) through to capital-intensive expansion and scale-up phases via dedicated funds like the Wachstumsfonds Bayern and ScaleUp-Fonds Bayern. [1]
• Regional mandate: Requires the company to have its seat in Bavaria or establish substantial value creation there, ensuring the state's economic development goals are met. [1]

Credibility: The investment mandate and ticket sizes are defined by the company's own website and Wikipedia entry detailing its history as a subsidiary of LfA Förderbank Bayern. [2][1]

Interconnection: The requirement for Bavarian value creation directly dictates the geographic eligibility and limits the addressable market to founders willing to anchor operations in the region.

Value add

• Long-term capital stability: As a state-owned entity, Bayern Kapital provides patient capital that is not subject to typical VC fund-duration exit pressures, allowing for longer development cycles. [2][1]
• Consortium leverage: Participation signals credibility to private investors, helping to attract additional national and international VCs and family offices to the round. [1]
• Regional network access: Provides direct links to the Bavarian innovation ecosystem, including the LfA Förderbank group and local industry partners. [1]
• Fit verdict: Ideal for Bavarian deep tech/high-tech founders who have secured private lead investors and need long-term, stable capital for scaling.
• Founder diligence script:

1. Do I have a private lead investor ready to syndicate with Bayern Kapital? 2. Is my company's seat or significant value creation firmly anchored in Bavaria? 3. Does my capital need extend beyond typical 7-10 year VC horizons to reach profitability? 4. Am I prepared for a consortium decision process rather than a single-investor term sheet?

Credibility: The long-term nature and consortium role are described in the website and Wikipedia entries. [2][1]

Interconnection: The consortium requirement means value add is realized through deal facilitation and signaling, not just capital provision.

Portfolio focus

• Deep Tech & Aerospace: Significant investments in Isar Aerospace (launch vehicles) and Quantum Systems (AI/aerial intelligence), indicating a strong appetite for capital-intensive, hard tech. [2][3]
• Life Sciences & Biotech: Portfolio includes Pieris Pharmaceuticals, Probiodrug, and mBiomics, showing active participation in the life sciences sector. [1][3]
• Enterprise Software & AI: Major holdings in commercetools (digital commerce), IQM (quantum computing), and SimScale (simulation software), highlighting a focus on scalable B2B tech. [2][3]
• Industrial Tech & IoT: Investments in EGYM (smart fitness), ProGlove (wearable scanners), and LUMA Vision (machine vision) demonstrate support for industrial and consumer tech hardware. [2][3]
• Exit success: Portfolio has generated 3 unicorns (IQM, Quantum Systems, tado°), 5 IPOs, and 42 acquisitions, proving a track record of high-value exits. [3]

Credibility: Portfolio companies and exit statistics are listed in the website highlights, Wikipedia entry, and Tracxn profile. [2][1][3]

Interconnection: The concentration in deep tech and life sciences confirms that founders in these sectors face the highest alignment with the fund's strategic mandate.

Notable investments & exits

• commercetools — Listed as a portfolio highlight with a successful exit, providing digital commerce solutions for global brands [1].
• DeepDrive — Invested in the developer of high-efficiency electric motors for the automotive industry [1].
• EGYM — Backed the provider of the most flexible, open ecosystem in the fitness industry, combining smart gym tech with software and services [1].
• Isar Aerospace — Invested in the company developing and building launch vehicles for the cost-efficient transport of small satellites into orbit [1].
• OroraTech — Supported the leading company for thermal-infrared based analyses using sensors in space [1].
• Proxima Fusion — Invested in the first spin-out of the Max Planck Institute for Plasma Physics, aiming to accelerate a paradigm shift in the energy sector [1].
• SimScale — Backed the cloud-based engineering simulation platform [1].
• SIRION — Invested in the developer of new AAV-based vectors for gene therapy, utilizing evolutionary principles [1].
• QuantumDiamonds — Recently invested €91 million in quantum-based microchip inspection technology [1].
• Maple Aviation — Invested in autonomous drone logistics for the healthcare sector [1].
• 3D Printing Company — Listed as a portfolio highlight providing holistic solutions in additive manufacturing with a successful exit [1].
• Antibody-Drug Conjugate Company — Listed as a portfolio highlight with a successful exit, focusing on new ways to treat cancer [1].